Antitumor effects of Endostar on non-Hodgkin's lymphoma by regulating endothelial progenitor cells through protein kinase B-dependent pathway.
Endothelial progenitor cells (EPCs) play an important role in non-Hodgkin's lymphoma (NHL) development. Endostar is an anti-angiogenic drug designed to stop cancer by nullifying a tumor's ability to obtain oxygen and nutrients. In this study, we examined the anti-angiogenic activities of Endostar on NHL cell lines and murine xenograft model of NHL in vitro and in vivo, respectively, and explored the underlying antiangiogenic mechanism of Endostar. Results showed that Endostar may inhibit the EPC proliferation by reducing the expression of p-protein kinase B, but not p-ERK expression. Our finding could lead to a better understanding of the effects of Endostar on NHL.